ArticleMolecular pharmaceutics2012
Antibacterial activities of liposomal linolenic acids against antibiotic-resistant Helicobacter pylori.
Article in Molecular pharmaceutics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 104 citations in OpenAlex.
- Encapsulation of Flucytosine into nanoliposomes for enhanced antifungal activity against Candida glabrata and Candida albicans.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- Phytochemistry, Ethnopharmacology, and Pharmacology ofPlants (Basel, Switzerland) · 2025Review
- Targeted nanomedicines for the treatment ofMaterials today. Bio · 2025Review
- Article
- Oleic acid enriched diet affects the metabolome composition of the hybrid grouper infected with vibriosis.Fish physiology and biochemistry · 2024Article
- Liposomal Antibiotic Booster Potentiates Carbapenems for Combating NDMs-Producing Escherichia coli.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Linolenic acid-metronidazole inhibits the growth ofWorld journal of gastroenterology · 2023Article
- How Charge, Size and Protein Corona Modulate the Specific Activity of Nanostructured Lipid Carriers (NLC) againstPharmaceutics · 2022Article
- A Bioluminescence-Based Drug Screen Identifies Activities of Fexinidazole and Its Metabolites againstAntibiotics (Basel, Switzerland) · 2022Article
- Recent Advances in the Development of Lipid-, Metal-, Carbon-, and Polymer-Based Nanomaterials for Antibacterial Applications.Nanomaterials (Basel, Switzerland) · 2022Review
- Linolenic Acid-Metronidazole: a Compound Relieving Drug Resistance and Inhibiting Helicobacter pylori.Antimicrobial agents and chemotherapy · 2022Article
- The Activity of Liposomal Linolenic Acid AgainstFrontiers in cellular and infection microbiology · 2022Article
- Lipid Nanoparticle Technology for Delivering Biologically Active Fatty Acids and Monoglycerides.International journal of molecular sciences · 2021Review
- Nano-fats for bugs: the benefits of lipid nanoparticles for antimicrobial therapy.Drug delivery and translational research · 2021Review
- Myricetin as an Antivirulence Compound Interfering with a Morphological Transformation into Coccoid Forms and Potentiating Activity of Antibiotics againstInternational journal of molecular sciences · 2021Article
- The Puzzle of Coccoid Forms ofAntibiotics (Basel, Switzerland) · 2020Review
- Antifungal Effect of Triglycerol Monolaurate Synthesized by Lipozyme 435-Mediated Esterification.Journal of microbiology and biotechnology · 2020Article
- Transformation ofPathogens (Basel, Switzerland) · 2020Review
- Inhibition ofExperimental biology and medicine (Maywood, N.J.) · 2020Article
- Recent Advances in Nanotechnology-Aided Materials in Combating Microbial Resistance and Functioning as Antibiotics Substitutes.International journal of nanomedicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Helicobacter pylori (H. pylori) infection with its vast prevalence is responsible for various gastric diseases including gastritis, peptic ulcers, and gastric malignancy. While effective, current treatment regimens are challenged by a fast-declining eradication rate due to the increasing emergence of H. pylori strains resistant to existing antibiotics. Therefore, there is an urgent need to develop novel antibacterial strategies against H. pylori. In this study, we developed a liposomal nanoformulation of linolenic acid (LipoLLA) and evaluated its bactericidal activity against resistant strains of H. pylori. Using a laboratory strain of H. pylori, we found that LipoLLA was effective in killing both spiral and coccoid forms of the bacteria via disrupting bacterial membranes. Using a metronidazole-resistant strain of H. pylori and seven clinically isolated strains, we further demonstrated that LipoLLA eradicated all strains of the bacteria regardless of their antibiotic resistance status. Furthermore, under our experimental conditions, the bacteria did not develop drug resistance when cultured with LipoLLA at various sub-bactericidal concentrations, whereas they rapidly acquired resistance to both metronidazole and free linolenic acid (LLA). Our findings suggest that LipoLLA is a promising antibacterial nanotherapeutic to treat antibiotic-resistant H. pylori infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.